亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台，協助業界發掘知識產權貿易商機，並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權，或是製造商需要購買技術以提高操作效能，又或是知識產權配套服務供應商，你將會從本網站發掘到有用的知識產權貿易資訊。

返回搜索結果

Anti-Diabetic and Anti-Obesity Therapeutic

技術優勢: Reduces adiposity without elevating plasma triglyceride levelsImproves glucose homeostasis by several potential mechanisms and directly targets both white and brown adipose tissue

技術應用: Anti-diabetic, anti-obesity therapeuticComposition for improving insulin sensitivity of obese and diabetic patients

*Abstract: Obesity and its associated metabolic diseases, including type 2 diabetes, are components of a global epidemic. However, the pharmacological approaches against obesity and metabolic diseases are limited. Research is growing on a secreted protein, Angiopoietin-like 4 (ANGPTL4), that inhibits lipoprotein lipase (LPL) activity and promotes lipolysis in adipocytes.

A UC Berkeley researcher is currently examining the role of ANGPTL4 and variants thereof, particularly the C-terminal fibrinogen-like domain (FLD) of ANGPTL4. Using animal models, the UC researcher found that increasing plasma FLD levels protected the animal from diet-induced obesity without affecting plasma triglyceride levels and improve glucose homeostasis. The discovery targets both white and brown adipose tissue, thus it provides a different approach to reduce obesity, complementing current pharmacological therapies. In addition, the discovery provides compositions and methods to improve insulin sensitivity in type 2 diabetes patients.

欲了解更多信息，請點擊這裡